✦ LIBER ✦

Daunorubicin vs idarubicin in paediatric AML

Book ID: 120860167
Publisher: Adis International Limited (now part of Wolters Kluwer Health)
Year: 2002
Weight: 133 KB
Volume: &NA;
Category: Article
ISSN: 1173-8324
DOI: 10.2165/00128413-200213670-00027

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Daunorubicin is less toxic than idarubic

Daunorubicin is less toxic than idarubicin in paediatric AML

✍ Baker, Holly 📂 Article 📅 2013 🏛 The Lancet 🌐 English ⚖ 255 KB

Idarubicin preferred to daunorubicin as

Idarubicin preferred to daunorubicin as AML induction therapy

📂 Article 📅 1998 🏛 Adis International Limited (now part of Wolters Kl ⚖ 165 KB

Liposomal daunorubicin + cytarabine effe

Liposomal daunorubicin + cytarabine effective in AML

📂 Article 📅 2001 🏛 Adis International Limited (now part of Wolters Kl ⚖ 121 KB

Clofarabine + daunorubicin shows promise

Clofarabine + daunorubicin shows promise in adult AML

📂 Article 📅 2006 🏛 Adis International Limited (now part of Wolters Kl ⚖ 133 KB

Comparative pharmacokinetic study of ida

Comparative pharmacokinetic study of idarubicin and daunorubicin in leukemia patients

✍ Dr J. Robert; F. Rigal-Huguet; P. Hurteloup 📂 Article 📅 1992 🏛 John Wiley and Sons 🌐 English ⚖ 365 KB

## Abstract We have studied the pharmacokinetics of idarubicin and daunorubicin in a total of 16 leukemic patients treated with one of these drugs associated with aracytine. The AUCs obtained for unchanged drugs were proportional to the dose, and the dose‐independent pharmacokinetic parameters were

Pravastatin potentially adds value to id

Pravastatin potentially adds value to idarubicin + cytarabine in AML

📂 Article 📅 2007 🏛 Adis International Limited (now part of Wolters Kl ⚖ 133 KB